GSK is a fully focused biopharma company. We prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease. At the heart of this is our R&D focus on the science of the immune system, human genetics, genomics and advanced technologies, and our world-leading capabilities in vaccines and medicines development. We focus on four therapeutic areas: infectious diseases, HIV, respiratory/immunology, and oncology,
European Commission authorises ViiV Healthcare’s Apretude (cabotegravir long-acting and tablets) for HIV prevention September 19, 2023 10:59am
Cabotegravir demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF tablets) in reducing the risk of HIV in clinical trials.
View this post
Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anaemia September 15, 2023 4:48pm
Ojjaara is a once-a-day, oral JAK1/JAK2 and activin A receptor type 1 (ACVR1) inhibitor.
View this post
GSK and Save the Children renew award-winning partnership, with focus on ‘zero dose’ children who have never received a vaccine September 14, 2023 4:00am
GSK and Save the Children renew their 10-year partnership for a further five years.
View this post
GSK regulatory submission for momelotinib for the treatment of myelofibrosis accepted for review by Japanese regulator September 11, 2023 3:00am
Submission included data from trials addressing clinical manifestations of myelofibrosis - splenomegaly, constitutional symptoms and anaemia
View this post
GSK’s regulatory submission accepted for review by Japanese regulator for use of Nucala (mepolizumab) in adults with chronic rhinosinusitis with nasal polyps September 1, 2023 2:55am
If approved, Nucala would be first anti-interleukin-5 biologic available in Japan for treatment of adults with CRSwNP
View this post
New Shingrix data demonstrate 100% vaccine efficacy in the prevention of shingles in adults aged 50 and over in China August 23, 2023 2:34am
No cases of shingles (herpes zoster) reported among the participants who received Shingrix in the randomised clinical trial
View this post
